[바이오사 리포트] GC셀, 1분기 적자 개선…CGT·BL 반등 카드로

GC Cell is strategically pivoting from pandemic-dependent diagnostic services toward high-value sectors like Cell and Gene Therapy (CGT) and specialized Bio Logistics to ensure sustainable growth. The domestic approval application for Fucaso, a CAR-T therapy, underscores their commitment to leveraging established commercialization expertise for a significant market turnaround.